RIPK3 and neoplasm: Although chemotherapeutics normally trigger cell death in RIP3-/- or MLKL-/- tumor cell death via caspase-3-dependent apoptosis, it is unable to induce systemic anti-tumor response and inhibit tumor growth in vivo, which indicates necroptosis pathway plays a potential role in ICD (29).